Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $7.46, but opened at $7.89. Recursion Pharmaceuticals shares last traded at $7.53, with a volume of 2,242,941 shares.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RXRX shares. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday. Finally, Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Stock Down 1.5 %

The stock’s 50 day moving average is $6.67 and its 200 day moving average is $7.29. The company has a market capitalization of $2.11 billion, a PE ratio of -4.84 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now owns 7,109,875 shares in the company, valued at $48,631,545. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,235 shares of company stock valued at $802,988 in the last quarter. 15.75% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. raised its position in shares of Recursion Pharmaceuticals by 58.9% during the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock valued at $127,000 after buying an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $89,000. Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Barclays PLC increased its position in shares of Recursion Pharmaceuticals by 53.9% during the 3rd quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after purchasing an additional 244,278 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at about $692,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.